Cancer Chemotherapy and Pharmacology

Volume 13 1984

Edited by

S.K. CARTER and T. McELWAIN

Editorial Board

M. Acton Menlo Park
P. Alberto Geneva
R. H. Blum New York
M. Boiron Paris
H. Calvert Sutton
R. L. Comis Syracuse
T. Connors Carshalton
R. C. Coombes Sutton
S. Eckhardt Budapest
R. M. Fox Sydney
B. W. Fox Manchester
S. Garattini Milano
M. Ghione Milano
H. Hansen Copenhagen
K. Karrer Vienne
D. L. Kisner Bethesda
J. Laszlo Durham
R. B. Livingston Seattle
J. S. Macdonald Bethesda
J. G. McVie Amsterdam
F. M. Muggia New York
M. Ogawa Tokyo
P. Martin Marseille
S. Pavlovsky Buenos Aires
P. Potier Gif-sur-Yvette
P. Reizenstein Stockholm
E. Robinson Haifa
M. Rozencweig Brussells
C. G. Schmidt Essen
H. J. Senn St. Gallen
J. Smyth Edinburgh
A. Trouet Brussells
S. Tsukagoshi Tokyo
U. Umezawa Tokyo
L. M. van Putten Rijswijk
F. A. Valeriote Detroit
P. Wilkinson Manchester
G. Wu Huan-Hsin Peking

Springer International

Cancer Chemotherapy and Pharmacology

This journal was founded in 1978. Editors: S. K. Carter, T. McElwain. Published by Springer International.

Copyright
Submission of a manuscript implies that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review or thesis), that it is not under consideration for publication elsewhere, that its publication has been approved by all the authors and by the responsible authorities – tacitly or explicitly – in the institutes where the work was carried out and that, if accepted, it will not be published elsewhere in the same form, in either the same or another language, without the consent of the copyright holders. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform, electronic data base, video disks, or any other reproductions of similar nature, and translations.

Photographic reproduction, microform electronic data base, video disks, or any other reproduction of text, figures, or tables from this journal is prohibited without permission obtained from the publisher.

The use of general descriptive names, trade names, trade marks, etc., in this publication, even if the former are not specifically identified, is not to be interpreted as exempt from the relevant protective laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for the USA

Photocopies may be made for personal or internal use beyond that permitted by Section 107 or 108 of the U.S. Copyright Law, provided a fee is paid. This fee is $ 0.20 per page or a minimum of $ 1.00 if an article consists of less than five pages. Please pay this fee to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0302-8933, volume, and first and last page numbers of each article copied.

The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying.

Other regulations

Authors of this journal can benefit from library and photocopy fees collected by VG WORT if certain conditions are met. If an author lives in the Federal Republic of Germany or in West Berlin it is recommended that he contact Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printed in Germany by v. Starck'sche Druckereigesellschaft m.b.H., D-6200 Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1984

Table of Contents

Adachi, K., see Inoue, K., et al. 95
Agoliati, G., see Engelking, C., et al. 150
Aherne, G. W., see Slevin, M. L., et al. 19
Alberto, P., see Joss, R. A., et al. 148
Albertson, D. A., see Jackson, D. V. Jr., et al. 120
Allan, S. G., Gregor, A., Cornbleet, M. A., Leonard, R. C. F., Smyth, J. F., Grant, I. W. B., Crompton, G. K.: Phase II trial of vindesine and VP16-213 in the palliaton of poor-prognosis patients and elderly patients with small cell lung cancer 106
Altenburg, H.-P., see Heim, M. E., et al. 123
Arlin, Z. A., see Engelking, C., et al. 150
Armand, J.-P., see Malet-Martino, M.-C., et al. 31
Au, J., see Sternberg, A., et al. 218

Baba, T., see Uozumi, J., et al. 82
Baker, L. H., see Schilcher, R. B., et al. 186
Baratz, M., see Inbar, M. J., et al. 71
Barnett, M., Richards, M., Hamilton, C., Lister, A., Treatment of myeloblastic sarcoma in the sacral canal with high-dose cytosine arabinoside 238
Barnett, M. J., see Harvey, V. J., et al. 91
Benington, F., see Khaled, M. A., et al. 73
Beránek, J., see Novotný, L., et al. 195
Bergmann, L., see Klippstein, T. H., et al. 78
Bernadou, J., see Malet-Martino, M.-C., et al. 31
Béteille, J.-P., see Malet-Martino, M.-C., et al. 31
Billiaert, P., see Welsh, J., et al. 151
Blackie, R. G. G., see Welsh, J., et al. 151
Bon, M., see Malet-Martino, M.-C., et al. 31
Borcich, J. K., see Levin, V. A., et al. 200
Boritzki, T. J., see Fry, D. W., et al. 171
Bradner, W. T., see Schurig, J. E., et al. 164
Breimer, D. D., see Teunissen, M. W. E., et al. 181
Bruntsch, U., Groos, G., Tigges, F.-J., Hofschneider, P. H., Gallmeier, W. M., Lack of response in nine patients with breast cancer treated with fibroblast interferon 39
Buice, R. G., Nieli, H. B., Sidhu, P., Gurley, B. J.: Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung 1
Burton, N. K., see Slevin, M. L., et al. 19
Byrd, D., see Levin, V. A., et al. 200

Caignard, A., see Chauffert, B., et al. 14
Calman, K. C., see Welsh, J., et al. 151
Campbell, J., see Levin, V. A., et al. 200
Caporali, C., see Cognetti, F., et al. 235
Carlini, P., see Cognetti, F., et al. 235
Carlsson, J., see Nederman, T. 131
Carter, S. K.: Perusing the ASCO abstracts with a focus on interferons in malignant melanoma and renal cell carcinoma 153
Cavalli, F., see Joss, R. A., et al. 148
Chadwick, G., see Wagstaff, J., et al. 100
Chaitchik, S., see Inbar, M. J., et al. 71
Chauffert, B., Martin, F., Caignard, A., Jeannin, J.-F., Leclerc, A.: Cytofluorescence localization of adriamycin in resistant colon cancer cells 14
Červek, J., see Kolarić, K., et al. 142
Cognetti, F., Pinnaro, P., Carlini, P., Caporali, C., Ruggeri, E. M., Pollera, C. F.: Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination 235
Colombo, T., D'Incalci, M.: Comparison of the antitumor activity of DTIC and 1-*p*-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on murine transplantable tumors and their hematological toxicity 139
Coombes, R. C., see Perez, D. J., et al. 36
Copley, M. P., see Osman, N. M., et al. 58
Cornbleet, M. A., see Allan, S. G., et al. 106
Creaven, P., see Sternberg, A., et al. 218
Crompton, G. K., see Allan, S. G., et al. 106
Crowther, D., see Wagstaff, J., et al. 100

Dalmark, M., see Johansen, P. B., et al. 5
Daugherty, J. P., see Khaled, M. A., et al. 73
Davis, R. L., see Levin, V. A., et al. 200
DeGregorio, M. W., Holleran, W. M., Macher, B. A., Linker, C. A., Wilbur, J. R.: Kinetics and sensitivity of daunorubicin in patients with acute leukemia 230
Deutsch, H. F., see Sasaki, T., et al. 75
Dieckman, J., see Valeriote, F., et al. 126
D'Incalci, M., see Colombo, T. 139
D'Incalci, M., see Rossi, C., et al. 211
Dong, G. W., Preisler, H. D., Priore, R.: Potential limitations of in vitro clonogenic drug sensitivity assays 206
Drewinko, B., see Grossie, V. B. Jr., et al. 27
Edanami, K., Komiyama, K., Kuroda, T., Umezawa, I.: Antitumor activity of a nitrosourea derivative, CNUA, on murine tumors 22
Engelking, C., Sullivan, P., Agoliati, G., Arlin, Z. A.: Amsacrine administration: A precautionary note 150
Eschalier, A., Lavarenne, J., Renoux, M.: Bronchopulmonary effects of elliptinium in anesthetized dogs 240

Farghali, H., see Novotný, L., et al. 195
Figer, A., see Inbar, M. J., et al. 71
Flentje, D., see Valeriote, F., et al. 126
Flentje, M., see Valeriote, F., et al. 126
Florczyk, A. P., see Schurig, J. E., et al. 164
Fodstad, Ø., see Godal, A., et al. 157
Forastiere, A. A., Perry, M. C., Hughes, A. K., Wood, W. C.: Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer. A Cancer and Leukemia Group B study 226
Ford, H. T., see Perez, D. J., et al. 36
Fox, B. W., see McGown, A. T., et al. 47
Fox, B. W., see Poppitt, D. G., et al. 43
Fox, B. W., see Poppitt, D. G., et al. 54
Fry, D. W., Boritzki, T. J., Jackson, R. C.: Studies on the biochemical mechanism of the novel antitumor agent, CI-920 171
Fujimoto, T., see Sasaki, K., et al. 9

Gallmeier, W. M., see Bruntsch, U., et al. 39
Gazet, J.-C., see Perez, D. J., et al. 36
Giavazzi, R., Kartner, N., Hart, I. R.: Expression of cell surface P-glycoprotein by an Adriamycin-resistant murine fibrosarcoma 145
Godal, A., Fodstad, Ø., Ingebrigtsen, K., Pihl, A.: Pharmacological studies of ricin in mice and humans 157
Grant, I. W. B., see Allan, S. G., et al. 106
Greaves, J., see Roboz, J., et al. 67
Gregor, A., see Allan, S. G., et al. 106
Groos, G., see Bruntsch, U., et al. 39
Grossie, V. B. Jr., Valdivieso, M., Drewinko, B., Loo, T. L.: Effect of thymidine on the toxicity and antitumor activity of *Cis*-diammine-dichloroplatinum (II) 27
Gurley, B. J., see Buice, R. G., et al. 1

Haim, N., Kedar, A., Robinson, E.: Methotrexate-related deaths in patients previously treated with *cis*-diamminedichloride platinum 223
Halbert, G., see Welsh, J., et al. 151
Hamilton, C., see Barnett, M., et al. 238
Hart, I. R., see Giavazzi, R., et al. 145
Harvey, V. J., Slevin, M. L., Woollard, R. C., Johnston, A., Barnett, M. J., Wrigley, P. F. M., Turner, P.: The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle 91
Harvey, V. J., see Slevin, M. L., et al. 19
Heim, M. E., Queißer, W., Altenburg, H.-P.: Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy 123
Hirai, H., see Sasaki, T., et al. 75

Hirth, R. S., see Schurig, J. E., et al. 164
Hofschneider, P. H., see Bruntsch, U., et al. 39
Holland, J. F., see Roboz, J., et al. 67
Holleran, W. M., see DeGregorio, M. W., et al. 230
Horikoshi, N., see Inoue, K., et al. 95
Hoshi, A., see Iigo, M. 86
Howell, A., see Wagstaff, J., et al. 100
Huftalen, J. B., see Schurig, J. E., et al. 164
Hughes, A. K., see Forastiere, A. A., et al. 226

Iigo, M., Hoshi, A.: Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia 86
Ikeda, K., see Inoue, K., et al. 95
Inagaki, J., see Inoue, K., et al. 95
Inbar, M. J., Baratz, M., Figer, A., Schpitzer-Reter, E., Chaitchik, S.: Idiosyncratic reaction to bleomycin in an epithelial tumor 71
Ingebrigtsen, K., see Godal, A., et al. 157
Inoue, K., Ogawa, M., Inagaki, J., Horikoshi, N., Miyamoto, H., Ikeda, K., Usui, N., Nakada, H., Adachi, K.: A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer 95
Ishizawa, M., see Uozumi, J., et al. 82
Iwamoto, Y., see Uozumi, J., et al. 82

Jackson, D. V., Jr., Long, T. R., Trahey, T. F., Morgan, T. M.: Synergistic antitumor activity of vincristine and VP-16-213 176
Jackson, D. V. Jr., Richards II., F., Spurr, C. L., Long, T. R., Rardin, D. A., Albertson, D. A., Sterchi, J. M.: Hepatic intra-arterial infusion of vincristine 120
Jackson, D. V. Jr., Sethi, V. S., Long, T. R., Muss, H. B., Spurr, C. L.: Pharmacokinetics of vindesine bolus and infusion 114
Jackson, R. C., see Fry, D. W., et al. 171
Janku, I., see Novotný, L., et al. 195
Jeannin, J.-F., see Chauffert, B., et al. 14
Jensen, S. E., see Johansen, P. B., et al. 5
Johansen, P. B., Jensen, S. E., Rasmussen, S. N., Dalmark, M.: Pharmacokinetics of doxorubicin and its metabolite doxorubicinol in rabbits with induced acid and alkaline urine 5
Johnston, A., see Harvey, V. J., et al. 91
Johnston, A., see Slevin, M. L., et al. 19
Jones, A. C., Wilson, P. A., Steel, G. G.: Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and *cis*-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8) 109
Joss, R. A., Obrecht, J. P., Jungi, W. F., Alberto, P., Sauter, C., Cavalli, F.: Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung 148
Jungi, W. F., see Joss, R. A., et al. 148

Karanes, C., see Schilcher, R. B., et al. 186
Kartner, N., see Giavazzi, R., et al. 145
Kedar, A., see Haim, N., et al. 223
Khaled, M. A., Morin, R. D., Benington, F., Daugherty, J. P.: 2,4-Diamino-6-(bis-2-chloroethyl)aminomethyl pteridine. A new potent anticancer drug 73
Klippstein, T. H., Mitrou, P. S., Kochendörfer, K. J., Bergmann, L.: High-dose adriamycin (ADM) and *cis*-platinum (DDP) in advanced soft-tissue sarcomas and invasive thymomas. A pilot study 78
Kochendörfer, K. J., see Klippstein, T. H., et al. 78
Kolarić, K., Roth, A., Vukas, D., Cervek, J.: CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study 142
Komiyama, K., see Edanami, K., et al. 22
Kufe, D. W., see Peters, W. P., et al. 136
Kuroda, T., see Edanami, K., et al. 22

Lavarenne, J., see Eschalier, A., et al. 240
Leclerc, A., see Chauffert, B., et al. 14
Leonard, R. C. F., see Allan, S. G., et al. 106
Levin, V. A., Byrd, D., Campbell, J., Davis, R. L., Borcich, J. K.: CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs 200
Linker, C. A., see DeGregorio, M. W., et al. 230
Lister, A., see Barnett, M., et al. 238
Litterst, C. L., see Osman, N. M., et al. 58
Long, T. R., see Jackson, D. V. Jr., et al. 114
Long, T. R., see Jackson, D. V. Jr., et al. 120
Long, T. R., see Jackson, D. V. Jr., et al. 176
Loo, T. L., see Grossie, V. B. Jr., et al. 27
Loo, T. L., see Lu, K., et al. 63
Lopez,A., see Malet-Martino, M.-C., et al. 31
Lu, K., Savaraj, N., Loo, T. L.: Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2[2-hydroxyethal)-amino]ethyl)amino]-9,10-anthracenedione dihydrochloride in the dog 63

Macher, B. A., see DeGregorio, M. W., et al. 230
Malet-Martino, M.-C., Martino, R., Lopez, A., Béteille, J.-P., Bon, M., Bernadou, J., Armand, J.-P.: New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR 31
Mangioni, C., see Rossi, C., et al. 211
Martin, F., see Chauffert, B., et al. 14
Martino, R., see Malet-Martino, M.-C., et al. 31
McGown, A. T., Poppitt, D. G., Swindell, R., Fox, B. W.: The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate-resistant (L1210/R7A) line, studied by flow cytometric and chromosome number analysis 47
McGown, A. T., see Poppitt, D. G., et al. 43
McGown, A. T., see Poppitt, D. G., et al. 54
Medoff, G., see Valeriote, F., et al. 126
Mitrou, P. S., see Klippstein, T. H., et al. 78
Mittelman, A., see Sternberg, A., et al. 218
Miyamoto, H., see Inoue, K., et al. 95
Momparler, L. F., see Momparler, R. L., et al. 191
Momparler, R. L., Samson, J., Momparler, L. F., Rivard, G. E.: Cell cycle effects and cellular pharmacology of 5-AZA-2′-deoxycytidine 191
Morgan, T. M., see Jackson, D. V. Jr., et al. 176
Morin, R. D., see Khaled, M. A., et al. 73
Murray, S. L., Du Vall, E. M., Slater, L. M.: Calcium modifies the accumulation and retention of daunorubicin by Ehrlich ascites carcinoma 69
Muss, H. B., see Jackson, D. V. Jr., et al. 114

Nakada, H., see Inoue, K., et al. 95
Naus, A., see Wils, J., et al. 215
Nederman, T., Carlsson, J.: Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids 131
Niell, H. B., see Buice, R. G., et al. 1
Novotný, L., Farghali, H., Ryba, M., Jank, I., Beránek, J.: Structure-intestinal transport and structure-metabolism correlations of some potential cancerostatic pyrimidine nucleosides in isolated rat jejunum 195

Obrecht, J. P., see Joss, R. A., et al. 148
Ogawa, M., see Inoue, K., et al. 95
Osman, N. M., Copley, M. P., Litterst, C. L.: Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats 58

Paciucci, P. A., see Roboz, J., et al. 67
Perez, D. J., Powles, T. J., Gazet, J.-C., Ford, H. T., Coombes, R. C.: Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer 36
Perry, M. C., see Forastiere, A. A., et al. 226

Peters, W. P., Weiss, G., Kufe, D. W.: Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU 136
Petrelli, N. J., see Sternberg, A., et al. 218
Pihl, A., see Godal, A., et al. 157
Pinnaro, P., see Cognetti, F., et al. 235
Pollera, C. F., see Cognetti, F., et al. 235
Poppitt, D. G., McGown, A. T., Fox, B. W.: Collateral sensitivity of a methotrexate-resistant L 1210 cell line to the vinca alkaloids 43
Poppitt, D. G., McGown, A. T., Fox, B. W.: The use of a fluorescent methotrexate probe to monitor the effects of three vinca alkaloids on a mixed population of parental L 1210 and gene-amplified methotrexate-resistant cells by flow cytometry 54
Poppitt, D. G., see McGown, A. T., et al. 47
Powles, T. J., see Perez, D. J., et al. 36
Preisler, H. D., see Dong, G. W., et al. 206
Priore, R., see Dong, G. W., et al. 206

Queißer, W., see Heim, M. E., et al. 123

Rardin, D. A., see Jackson, D. V. Jr., et al. 120
Rasmussen, S. N., see Johansen, P. B., et al. 5
Ratanatharathorn, V., see Schilcher, R. B., et al. 186
Renoux, M., see Eschalier, A., et al. 240
Richards, F. II, see Jackson, D. V. Jr., et al. 120
Richards, M., see Barnett, M., et al. 238
Rivard, G. E., see Momparler, R. L., et al. 191
Robinson, E., see Haim, N., et al. 223
Roboz, J., Paciucci, P. A., Silides, D., Greaves, J., Holland, J. F.: Detection and quantification of mitoxantrone in human organs. A case report 67
Rose, W. C., see Schurig, J. E., et al. 164
Rossi, C., Zucchetti, M., Sessa, C., Urso, R., Mangioni, C., D'Incalci, M.: Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients 211
Roth, A., see Kolarić, K., et al. 142
Ruggeri, E. M., see Cognetti, F., et al. 235
Rustum, Y., see Sternberg, A., et al. 218
Ryba, M., see Novotný, L., et al. 195

Samson, J., see Momparler, R. L., et al. 191
Sasaki, K., Tanaka, J., Fujimoto, T.: Theoretically required urinary flow during high-dose methotrexate infusion 9
Sasaki, T., Tsukada, Y., Deutsch, H. F., Hirai, H.: Daunomycin-arachidonic acid complex as a potential new antitumor agent 75
Sauter, C., see Joss, R. A., et al. 148
Savaraj, N., see Lu, K., et al. 63
Scarffe, J. H., see Wagstaff, J., et al. 100
Schilcher, R. B., Young, J. D., Ratanatharathorn, V., Karanes, C., Baker, L. H.: Clinical pharmacokinetics of high-dose mitomycin C 186
Schlangen, J., see Wils, J., et al. 215
Schlein, A., see Schurig, J. E., et al. 164
Schpitzer-Reter, E., see Inbar, M. J., et al. 71
Schurig, J. E., Rose, W. C., Hirth, R. S., Schlein, A., Huftalen, J. B., Florczyk, A. P., Bradner, W. T.: Tallysomycin $S_{10}b$: Experimental antitumor activity and toxicity 164
Sessa, C., see Rossi, C., et al. 211
Setanoians, A., see Welsh, J., et al. 151
Sethi, V. S., see Jackson, D. V. Jr., et al. 114
Sidhu, P., see Buice, R. G., et al. 1
Silides, D., see Roboz, J., et al. 67
Slater, L. M., see Murray, S. L., et al. 69
Sleijfer, D. T., see Teunissen, M. W. E., et al. 181
Slevin, M. L., Harvey, V. J., Aherne, G. W., Burton, N. K., Johnston, A., Wrigley, P. F. M.: Delayed-release bleomycin. Comparative pharmacology of bleomycin oil suspension and bleomycin in saline 19
Slevin, M. L., see Harvey, V. J., et al. 91
Sluiter, W. J., see Teunissen, M. W. E., et al. 181
Smyth, J. F., see Allan, S. G., et al. 106
Spurr, C. L., see Jackson, D. V. Jr., et al. 114
Spurr, C. L., see Jackson, D. V. Jr., et al. 120
Steel, G. G., see Jones, A. C., et al. 109
Sterchi, J. M., see Jackson, D. V. Jr., et al. 120
Sternberg, A., Petrelli, N. J., Au, J., Rustum, Y., Mittelman, A., Creaven, P.: A combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma 218
Stuart, J. F. B., see Welsh, J., et al. 151
Sullivan, P., see Engelking, C., et al. 150
Swindell, R., see McGown, A. T., et al. 47

Tanaka, J., see Sasaki, K., et al. 9
Teunissen, M. W. E., Willemse, P. H. B., Sleijfer, D. T., Sluiter, W. J., Breimer, D. D.: Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment 181
Thatcher, N., see Wagstaff, J., et al. 100
Tigges, F.-J., see Bruntsch, U., et al. 39
Trahey, T. F., see Jackson, D. V. Jr., et al. 176
Tsukada, Y., see Sasaki, T., et al. 75
Turner, P., see Harvey, V. J., et al. 91

Umezawa, I., see Edanami, K., et al. 22
Uozumi, J., Ishizawa, M., Iwamoto, Y., Baba, T.: Sodium thiosulfate inhibits *cis*-diamminedichloroplatinum (II) activity 82
Urso, R., see Rossi, C., et al. 211
Usui, N., see Inoue, K., et al. 95

Valdivieso, M., see Grossie, V. B. Jr., et al. 27
Valeriote, F., Dieckman, J., Flentje, D., Flentje, M., Medoff, G.: Potentiation by amphotericin B of the cytotoxicity of anticancer agents against MOPC-315 plasmacytoma and Lewis lung carcinoma 126
Vall, E. M. Du, see Murray, S. L., et al. 69
Vukas, D., see Kolarić, K., et al. 142

Wagstaff, J., Chadwick, G., Howell, A., Thatcher, N., Scarffe, J. H., Crowther, D.: A phase I toxicity study of human rDNA interferon in patients with solid tumours 100
Weiss, G., see Peters, W. P., et al. 136
Welsh, J., Stuart, J. F. B., Setanoians, A., Blackie, R. G. G., Billiaert, P., Halbert, G., Calman, K. C.: The analysis and animal pharmacokinetics of 1,2,4, triglycidyl urazol using a high-pressure liquid chromatographic technique. Cancer Chemother Pharmacol 12 : 198–200 (Erratum) 151
Wilbur, J. R., see DeGregorio, M. W., et al. 230
Willemse, P. H. B., see Teunissen, M. W. E., et al. 181
Wils, J., Schlangen, J., Naus, A.: Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma 215
Wilson, P. A., see Jones, A. C., et al. 109
Wood, W. C., see Forastiere, A. A., et al. 226
Woollard, R. C., see Harvey, V. J., et al. 91
Wrigley, P. F. M., see Harvey, V. J., et al. 91
Wrigley, P. F. M., see Slevin, M. L., et al. 19

Young, J. D., see Schilcher, R. B., et al. 186

Zucchetti, M., see Rossi, C., et al. 211

Subject index

A
Acetazolamide 58
Adriamycin 14, 78, 215
– resistance 145
AFP 75
Alpha-2-interferon 100
Amphotericin B 126
Amsacrine administration 150
Antiemetic activiy of levonentradol/metoclopramide 123
Antipyrine 181
5-Aza-2′-deoxycytidine 191

B
Bisantrene 226
Bleomycin 71
– Delayed release 19
Breast cancer 36, 95, 142, 226

C
CAP vs CMFVP 142
Carboplatin 109
Cell cycle effects 191
Chemotherapy 36, 95
CI-920 171
Cisplatin 58, 235
Cis-platinum 223
Cis-platinum (II) 82, 109
Clonogenic assay 206
CNS 200
CNUA 22
Colon cancer 14
Colorectal carcinoma 215, 218
Combination therapy 142
Cytosine arabinoside 238
Cytotoxicity 191

D
Daunomycin 75
Daunorubicin 69, 230
5′-Deoxy-5-fluorouridine 31
DFMO 200
DGAQ 63
2,4-Diamino-6-(bis-2-chloroethyl)-aminoethyl pteridine 73
Dimethyltriazenes 139
Doxorubicin 5
Drug sensitivity assay 206
Drug studies 131

E
Elliptinium 240

F
5-F infusion 136
Fluoropyrimidines 31
5-Fluorouracil 131, 215, 218
^{19}FNMR 31

G
Guanosine 86

H
Hepatic artery infusion 120
Hexamethylmelamine 148
HPLC 75
Human leukemia 230
Hydration 9
7-Hydroxy-methotrexate 9

I
Intestinal transport of pyrimidine nucleosides 195
Interferon 153
Interferon-β 39

L
L1210 47, 54

M
Malignant melanoma 153
Mannitol 58
Melphalan 36, 109
Methotrexate 9, 36, 43, 54, 223
– bioavailability 91
Metoclopramide-dexamethasone combination emesis 235
MGBG 200
Mytomycin C 1, 36, 186, 215
Mitoxantrone 67
MMPR infusion 136
Murine fibrosarcoma 145
– tumor 22
Mutagenicity 191
Myeloblastic sarcoma 238

N
Nephrotoxicity 58
Nitrosoureas 22
Non-oat cell lung cancer 1

O
Ovarian cancer 211
Ovarian carcinoma xenografts 109

P
Pharmacokinetics 5, 200, 211, 230
Pharmacology 63
Phase II study 226
P-glycoprotein 145
P388 leukemia 86

R
Ricin 157

S
Sensitivity 230
Small cell lung cancer 106, 148
Sodium thiosulfate 82
Spheroids 131

T
Tallysomycin $S_{10}b$ 164
Testicular cancer 181
Thymidine 218
– and DDP toxicity 27

U
Urinary alkalinization 9

V
Vinblastine 131
Vinca alkaloids 47, 54
Vincristine 120, 176
Vindesine 106, 148
– pharmacokinetics 114
VM26 211
VP16–213 106, 176